NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its fiscal fourth quarter and year-ended September 30, 2017 prior to market open on Friday, December 15, 2017. The Company will also hold a live investor conference call and webcast at 8:30am Eastern Time.
| Conference Call & Webcast | |||
| Friday, December 15 @ 8:30am Eastern Time | |||
| Domestic: | 877-407-0789 | ||
| International: | 201-689-8562 | ||
| Conference ID: | 13674508 | ||
| Webcast: | http://public.viavid.com/index.php?id=127596 | ||
| Replays – Available through December 22, 2017 | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Conference ID: | 13674508 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial (the MAKO study) for the treatment of the wet form of age-related macular degeneration. Topline data from the MAKO study is expected in early 2018. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact:
Ohr Pharmaceutical, Inc.
Investor Relations
888-388-2327
ir@ohrpharmaceutical.com
LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com